Molecular analysis of the molecular target drugs in brain tumors.

• Project/Area Number: 24791511
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Cerebral neurosurgery
• Research Institution: Oita University
• Principal Investigator: MORISHIGE MASAKI 大分大学, 医学部, 客員研究員 (60381050)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000); Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
• Keywords: 神経膠芽腫 / 浸潤 / 分子標的薬剤

Outline of Final Research Achievements

Glioblastoma multiforme (GBM) is the most invasive form in gliomas and extremely refractory to therapy. An investigation of the molecules regulating invasion will thus contribute to the GBM treatment. We have previously shown that GEP100 plays an important role in the invasive activities of human breast cancer. The GEP100, activated by receptor tyrosine kinases, appears to be common in angiogenesis and cancer invasion.
We here found that GEP100 is highly expressed in GBM cell lines correlated with invasive activity, and GEP100 tend to be expressed with RTK in GBM by immune-histochemical analysis. Our results indicate that GEP100 is one of the major components of GBM invasion.